Literature DB >> 15297948

Treatment of metastatic esophagus and gastric cancer.

Manish A Shah1, Gary K Schwartz.   

Abstract

Cancers of the upper gastrointestinal tract include cancers of the esophagus, gastroesophageal junction, and stomach. Metastatic or unresectable upper gastrointestinal malignancies are incurable but do benefit from palliative chemotherapy. Several agents have been examined in the treatment of these diseases, with modest single-agent activity. In combination, these chemotherapeutic agents demonstrate improved antitumor activity with acceptable toxicity. Several combination therapies have been developed and have been examined in recent large phase III randomized clinical trials. These studies, for the most part, have failed to demonstrate a survival advantage over the reference arm. However, with the examination of newer cytotoxic agents, as well as with the application of molecularly targeted approaches to upper gastrointestinal malignancies, there remains hope for improved therapies for these diseases in the future.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297948     DOI: 10.1053/j.seminoncol.2004.04.013

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  10 in total

1.  Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus.

Authors:  Z Zhong; X Gu; Z Zhang; D Wang; Y Qing; M Li; N Dai
Journal:  Br J Radiol       Date:  2012-08-16       Impact factor: 3.039

2.  Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin.

Authors:  Eric D Tetzlaff; Josephine Faust; Jaffer A Ajani
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

3.  A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.

Authors:  J A Chan; L S Blaszkowsky; P C Enzinger; D P Ryan; T A Abrams; A X Zhu; J S Temel; D Schrag; P Bhargava; J A Meyerhardt; B M Wolpin; P Fidias; H Zheng; S Florio; E Regan; C S Fuchs
Journal:  Ann Oncol       Date:  2011-01-07       Impact factor: 32.976

Review 4.  Gastric cancer: an update.

Authors:  Manish A Shah
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

5.  Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.

Authors:  William P Tew; Delia Radovich; Eileen O'Reilly; Gary Schwartz; Deborah Schrag; Leonard B Saltz; David P Kelsen; Stacey Kepler; David H Ilson
Journal:  Invest New Drugs       Date:  2008-10-28       Impact factor: 3.850

6.  Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept.

Authors:  Tomislav Dragovich; Christopher Campen
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

7.  Incorporation of biologic therapies in the management of gastroesophageal cancers.

Authors:  Minaxi Jhawer; David Kelsen; Manish Shah
Journal:  Gastrointest Cancer Res       Date:  2007-03

8.  Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.

Authors:  Chiara Arienti; Michele Zanoni; Sara Pignatta; Alberto Del Rio; Silvia Carloni; Michela Tebaldi; Gianluca Tedaldi; Anna Tesei
Journal:  Oncotarget       Date:  2016-04-05

9.  Long Term Complete Remission in Advanced Gastric Adenocarcinoma With Docetaxel, Oxaliplatin and Capecitabine Combination Regimen.

Authors:  Gaurav Goel
Journal:  World J Oncol       Date:  2012-07-05

10.  Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.

Authors:  T Takayama; Y Sato; T Sagawa; T Okamoto; H Nagashima; Y Takahashi; H Ohnuma; G Kuroiwa; K Miyanishi; R Takimoto; T Matsunaga; J Kato; K Yamaguchi; K Hirata; Y Niitsu
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.